Sjögren's syndrome: From pathogenesis to novel therapeutic targets

Clinical and Experimental Rheumatology

Volumn 34, Issue , 2016, Pages 58-62

  Barone, Francesca ^a   Colafrancesco, Serena ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Biologics; Chemokines; Cytokines; Primary Sj gren's syndrome; Stromal cells; TLOs

Indexed keywords

B CELL ACTIVATING FACTOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 22; LA ANTIBODY; RITUXIMAB; RO ANTIBODY; STROMAL CELL DERIVED FACTOR 1; ANTIINFLAMMATORY AGENT; AUTACOID; CYTOKINE;

ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BIOLOGICAL THERAPY; DISEASE ACTIVITY; GENETIC PREDISPOSITION; HUMAN; KERATOCONJUNCTIVITIS SICCA; LYMPHOID TISSUE; MUCOSAL ASSOCIATED LYMPHOID TISSUE; NONHODGKIN LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; SALIVARY GLAND BIOPSY; SJOEGREN SYNDROME; STROMA CELL; STUDY DESIGN; TERTIARY LYMPHOID STRUCTURE; TRANSCRIPTOMICS; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNITY; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME; T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNITY; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME; STROMAL CELLS; T-LYMPHOCYTES;

EID: 84984861469     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. BRENNAN MT, FOX PC: Sex differences in primary Sjögren's syndrome. J Rheumatol 1999; 26: 2373-6.
2. BOWMAN SJ, PILLEMER S, JONSSON R et al.: Revisiting Sjögren's syndrome in the new millennium: perspectives on assessment and outcome measures. Report of a workshop held on 23 March 2000 at Oxford, UK. Rheumatology 2001; 40: 1180-8.
3. FOX RI, TORNWALL J, MICHELSON P: Current issues in the diagnosis and treatment of Sjögren's syndrome. Curr Opin Rheumatol 1999; 11: 364-71.
4. VITALI C, BOMBARDIERI S, JONSSON R et al.: Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-8.
5. ANAYA JM, DELGADO-VEGA AM, CASTIBLANCO J: Genetic basis of Sjögren's syndrome. How strong is the evidence? Clin Dev Immunol 2006; 13: 209-22.
6. RAMOS-CASALS M, BRITO-ZERON P, SEROR R et al.: Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology 2015; 54: 2230-8.
7. GONZALEZ S, SUNG H, SEPULVEDA D, GONZALEZ M, MOLINA C: Oral manifestations and their treatment in Sjögren's syndrome. Oral Dis 2014; 20: 153-61.
8. BRITO-ZERON P, RAMOS-CASALS M: [Prognosis of patients with primary Sjögren's syndrome]. Med Clin (Barc.) 2008; 130: 109-115.
9. THEANDER E, HENRIKSSON G, LJUNGBERG O, MANDL T, MANTHORPE R, JACOBSSON LT: Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006; 65: 796-803.
10. VOULGARELIS M, DAFNI UG, ISENBERG DA, MOUTSOPOULOS HM: Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum 1999; 42: 1765-72.
11. ANAYA JM, TOBON GJ, VEGA P, CASTIBLANCO J: Autoimmune disease aggregation in families with primary Sjögren's syndrome. J Rheumatol 2006; 33: 2227-34.
12. BRITO-ZERON P, SORIA N, MUNOZ S et al.: Prevalence and clinical relevance of autoimmune neutropenia in patients with primary Sjögren's syndrome. Semin Arthritis Rheum 2009; 38: 389-95.
13. CALLAGHAN R, PRABU A, ALLAN RB et al.: Direct healthcare costs and predictors of costs in patients with primary Sjögren's syndrome. Rheumatology 2007; 46: 105-11.
14. BOWMAN SJ, ST PIERRE Y, SUTCLIFFE N et al.: Estimating indirect costs in primary Sjögren's syndrome. J Rheumatol 2010; 37: 1010-5.
15. LENDREM D, MITCHELL S, McMEEKIN P et al.: Health-related utility values of patients with primary Sjögren's syndrome and its predictors. Ann Rheum Dis 2014; 73: 1362-8.
16. JUAREZ M, TOMS TE, DE PABLO P et al.: Cardiovascular risk factors in women with primary Sjögren's syndrome: United Kingdom primary Sjögren's syndrome registry results. Arthritis Care Res 2014; 66: 757-64.
17. KOTSIS K, VOULGARI PV, TSIFETAKI N, DROSOS AA, CARVALHO AF, HYPHANTIS T: Illness perceptions and psychological distress associated with physical health-related quality of life in primary Sjögren's syndrome compared to systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int 2014; 34: 1671-81.
18. LENDREM D, MITCHELL S, McMEEKIN P et al.: Health-related utility values of patients with primary Sjögren's syndrome and its predictors. Ann Rheum Dis 2014; 73: 1362-8.
19. BARONE F, NAYAR S, CAMPOS J et al.: IL-22 regulates lymphoid chemokine production and assembly of tertiary lymphoid organs. Proc Natl Acad Sci USA 2015; 112: 11024-9.
20. CICCIA F, GUGGINO G, RIZZO A et al.: Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjögren's syndrome. Ann Rheum Dis 2012; 71: 295-301.
21. BOMBARDIERI M, McINNES IB, PITZALIS C: Interleukin-18 as a potential therapeutic target in chronic autoimmune/inflammatory conditions. Expert Opin Biol Ther 2007; 7: 31-40.
22. BOMBARDIERI M, BARONE F, PITTONI V et al.: Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjögren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate. Arthritis Res Ther 2004; 6: R447-456.
23. SADA PR, ISENBERG D, CIURTIN C: Biologic treatment in Sjögren's syndrome. Rheumatology 2015; 54: 219-230.
24. TISHLER M, YARON I, GEYER O, SHIRAZI I, NAFTALIEV E, YARON M: Elevated tear interleukin-6 levels in patients with Sjogren syndrome. Ophthalmology 1998; 105: 2327-9.
25. GARCIC-CARRASCO M, FONT J, FILELLA X et al.: Circulating levels of Th1/Th2 cytokines in patients with primary Sjögren's syndrome: correlation with clinical and immunological features. Clin Exp Rheumatol 2001; 19: 411-5.
26. BOUMBA D, SKOPOULI FN, MOUTSOPOULOS HM: Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjögren's syndrome. Br J Rheumatol 1995; 34: 326-33.
27. MOUTSOPOULOS NM, KATSIFIS GE, ANGELOV N et al.: Lack of efficacy of etanercept in Sjögren's syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. Ann Rheum Dis 2008; 67: 1437-43.
28. SEROR R, RAVAUD P, BOWMAN SJ et al.: EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann Rheum Dis 2010; 69: 1103-9.
29. SEROR R, BOOTSMA H, SARAUX A et al.: Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis 2016; 75: 382-9.
30. SEROR R, BOWMAN SJ, BRITO-ZERON P et al.: EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide. RMD Open. 2015; 1(1):e000022.
31. CHO HJ, YOO JJ, YUN CY, KANG EH, LEE HJ, HYON JY et al.: The EULAR Sjögren's syndrome patient reported index as an independent determinant of health-related quality of life in primary Sjögren's syndrome patients: in comparison with non-Sjögren's sicca patients. Rheumatology (Oxford). 2013; 52: 2208-17.
32. ONI C, MITCHELL S, JAMES K et al.: Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry. Rheumatology 2016; 55: 544-52.
33. MINGUENEAU M, BOUDAOUD S, HASKETT S et al.: Cytometry by time-of-flight immunophenotyping identifies a blood Sjögren's signature correlating with disease activity and glandular inflammation. J Allergy Clin Immunol 2016; 137: 1809-21.
34. DEVAUCHELLE-PENSEC V, CAGNARD N, PERS JO, YOUINOU P, SARAUX A, CHIOCCHIA G: Gene expression profile in the salivary glands of primary Sjögren's syndrome patients before and after treatment with rituximab. Arthritis Rheum 2010; 62: 2262-71.
35. DELLI K, HAACKE EA, IHRLER S et al.: Need for consensus guidelines to standardise the assessment of germinal centres and other histopathological parameters in salivary gland tissue of patients with primary Sjögren's syndrome. Ann Rheum Dis 2016; 75: e32.
36. DELLI K, HAACKE EA, KROESE FG et al.: In primary Sjögren's syndrome high absolute numbers and proportions of B cells in parotid glands predict responsiveness to rituximab as defined by ESSDAI, but not by SSRI. Ann Rheum Dis 2016; 75: e34.
37. DELLI K, HAACKE EA, KROESE FG et al.: Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment. Ann Rheum Dis 2016 Jan 12. [Epub ahead of print].
38. CORNEC D, COSTA S, DEVAUCHELLEPENSEC V, CHICHE L, SARAUX A, PERS JO: Do high numbers of salivary gland-infiltrating B cells predict better or worse outcomes after rituximab in patients with primary Sjögren's syndrome? Ann Rheum Dis 2016; 75: e33.
39. THEANDER E, VASAITIS L, BAECKLUND E et al.: Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. Ann Rheum Dis 2011; 70: 1363-8.
40. RISSELADA AP, LOOIJE MF, KRUIZE AA, BIJLSMA JW, VAN ROON JA: The role of ectopic germinal centers in the immunopathology of primary Sjögren's syndrome: a systematic review. Semin Arthritis Rheum 2013; 42: 368-76.
41. BOMBARDIERI M, BARONE F, HUMBY F et al.: Activation-induced cytidine deaminase expression in follicular dendritic cell networks and interfollicular large B cells supports functionality of ectopic lymphoid neogenesis in autoimmune sialoadenitis and MALT lymphoma in Sjögren's syndrome. J Immunol 2007; 179: 4929-38.
42. HUMBY F, BOMBARDIERI M, MANZO A et al.: Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med 2009; 6(1): e1.
43. DE VITA S, QUARTUCCIO L, SALVIN S et al.: Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for longterm efficacy. Clin Exp Rheumatol 2014; 32: 490-4.
44. QUARTUCCIO L, FABRIS M, SALVIN S, MASET M, DE MARCHI G, DE VITA S: Controversies on rituximab therapy in sjogren syndrome-associated lymphoproliferation. Int J Rheumatol 2009; 2009: 424935.
45. QUARTUCCIO L, FABRIS M, MORETTI M et al.: Resistance to rituximab therapy and local BAFF overexpression in Sjögren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. Open Rheumatol J 2008; 2: 38-43.
46. BUCKLEY CD, BARONE F, NAYAR S, BENEZECH C, CAAMANO J: Stromal cells in chronic inflammation and tertiary lymphoid organ formation. Annu Rev Immunol 2015; 33: 715-45.
47. FLETCHER AL, ACTON SE, KNOBLICH K: Lymph node fibroblastic reticular cells in health and disease. Nat Rev Immunol 2015; 15: 350-61.
48. DENTON AE, ROBERTS EW, LINTERMAN MA, FEARON DT: Fibroblastic reticular cells of the lymph node are required for retention of resting but not activated CD8+ T cells. Proc Natl Acad Sci USA 2014; 111: 12139-44.
49. CREMASCO V, WOODRUFF MC, ONDER L et al.: B cell homeostasis and follicle confines are governed by fibroblastic reticular cells. Nat Immunol 2014; 15: 973-81.
50. ACTON SE, FARRUGIA AJ, ASTARITA JL et al.: Dendritic cells control fibroblastic reticular network tension and lymph node expansion. Nature 2014; 514: 498-502.
51. SIEGERT S, LUTHER SA: Positive and negative regulation of T cell responses by fibroblastic reticular cells within paracortical regions of lymph nodes. Front Immunol 2012; 3: 285.
52. SIEGERT S, HUANG HY, YANG CY et al.: Fibroblastic reticular cells from lymph nodes attenuate T cell expansion by producing nitric oxide. PloS One 2011; 6: e27618.
53. LUKACS-KORNEK V, MALHOTRA D, FLETCHER AL et al.: Regulated release of nitric oxide by nonhematopoietic stroma controls expansion of the activated T cell pool in lymph nodes. Nat Immunol 2011; 12: 1096-104.
54. FLETCHER AL, LUKACS-KORNEK V, REYNOSO ED et al.: Lymph node fibroblastic reticular cells directly present peripheral tissue antigen under steady-state and inflammatory conditions. J Exp Med 2010; 207: 689-97.
55. VEGA F, COOMBES KR, THOMAZY VA, PATEL K, LANG W, JONES D: Tissue-specific function of lymph node fibroblastic reticulum cells. Pathobiology 2006; 73: 71-81.
56. KATAKAI T, HARA T, SUGAI M, GONDA H, SHIMIZU A: Lymph node fibroblastic reticular cells construct the stromal reticulum via contact with lymphocytes. J Exp Med 2004; 200: 783-95.
57. BARONE F, BOMBARDIERI M, ROSADO MM et al.: CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjögren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J Immunol 2008; 180: 5130-40.
58. PERS JO, DEVAUCHELLE V, DARIDON C et al.: BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum 2007; 56: 1464-77.
59. NOCTURNE G, MARIETTE X: Sjögren's Syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol 2015; 168: 317-27.
60. BARONE F, BOMBARDIERI M, MANZO A et al.: Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjögren's syndrome. Arthritis Rheum 2005; 52: 1773-84.
61. AMFT N, CURNOW SJ, SCHEEL-TOELLNER D et al.: Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjögren's syndrome. Arthritis Rheum 2001; 44: 2633-41.
62. NGO VN, KORNER H, GUNN MD et al.: Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J Exp Med 1999; 189: 403-12.
63. ANSEL KM, NGO VN, HYMAN PL et al.: A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000; 406: 309-14.